Patent classifications
G01N33/66
DEVELOPMENT OF BLOOD FIBROSIS MARKER FOR NON-ALCOHOLIC STEATOHEPATITIS
A method for evaluating the progression of hepatic fibrosis in non-alcoholic steatohepatitis, said method comprising measuring the amount of a sugar chain having a structure represented by formula (I) and/or a precursor sugar chain of the biosynthesis of a sugar chain having a structure represented by formula (I) in a sample.
METHIONINE CONCENTRATION MEASUREMENT METHOD
A method of using a graphite electrode to measure a concentration of glucose or methionine from a biological sample is described. A mechanical pencil lead may be used as the graphite electrode, and the biological sample may come from a patient's serum. The glucose or methionine may produce a peak current response within a range of 0.4-0.8 V when the sample is subjected to linear scan voltammetry.
METHIONINE CONCENTRATION MEASUREMENT METHOD
A method of using a graphite electrode to measure a concentration of glucose or methionine from a biological sample is described. A mechanical pencil lead may be used as the graphite electrode, and the biological sample may come from a patient's serum. The glucose or methionine may produce a peak current response within a range of 0.4-0.8 V when the sample is subjected to linear scan voltammetry.
Point-of-care apparatus and methods for analyte detections using electrochemical impedance or capacitance
The presence of analytes can be detected in the bodily fluid using Electrochemical Impedance Spectroscopy (EIS) or Electrochemical Capacitance Spectroscopy (ECS) in devices, such as handheld point-of-care devices. The devices, as well as systems and methods, utilize using Electrochemical Impedance Spectroscopy (EIS) or Electrochemical Capacitance Spectroscopy (EIS) in combination with an antibody or other target-capturing molecule on a working electrode. Imaginary impedance or phase shift, as well as background subtraction, also may be utilized.
Point-of-care apparatus and methods for analyte detections using electrochemical impedance or capacitance
The presence of analytes can be detected in the bodily fluid using Electrochemical Impedance Spectroscopy (EIS) or Electrochemical Capacitance Spectroscopy (ECS) in devices, such as handheld point-of-care devices. The devices, as well as systems and methods, utilize using Electrochemical Impedance Spectroscopy (EIS) or Electrochemical Capacitance Spectroscopy (EIS) in combination with an antibody or other target-capturing molecule on a working electrode. Imaginary impedance or phase shift, as well as background subtraction, also may be utilized.
LABEL-FREE N-GLYCAN QUANTIFICATION METHODS
This disclosure provides a novel label-free N-glycan analysis method to detect and quantify N-glycans and N-linked glycosylation profiles without using a label, such as a fluorescent label. This method allows for reduced sample preparation and chromatographic separation times, and can be used for product batch release.
Use of Glucose Control Indicators for Risk Assessment and Treatment of Neurodevelopmental Disorders and Techniques for Establishing the Status of Chronic Glucose Control
Dysglycemia as a risk factor for neurodevelopmental disorder or developmental diabetes. The risk is assessed based on measurement of a glucose control indicator in a blood sample. One particular example of a neurodevelopmental disorder is retinopathy of prematurity in an infant. One particular example of a glucose control indicator is ‘comprehensive glycated hemoglobin fraction’ or ‘comprehensive glycated albumin fraction.’ This is calculated using ‘total whole blood protein’ in the denominator. In the case of chronic hyperglycemia, there is an increased risk of proliferative retinopathy of prematurity. In the case of chronic hypoglycemia, there is an increased risk of non-proliferative retinopathy of prematurity. This ‘total whole blood protein’ technique could also be used to determine the glucose control status in other types of patients.
Vertical flow assay device for detecting glucose concentration in a fluid sample
A glycemic management related analyte detecting assay device (10) and method are provided for detecting and quantifying analyte concentrations in a fluid sample. The assay device includes an absorbent body containing an assay forming a detection zone for receiving a fluid test sample. The absorbent body is provided in a chamber of the device. The assay can detect one or more of a glycemic analyte selected from the group consisting of fasting plasma blood glucose, oral glucose, % glycated hemoglobin, and fasting insulin concentrations. In one embodiment, a container includes an absorbent body having a plurality of superimposed membranes (30, 32, 34, 36) where each membrane contains a reactant and a color indicator for detecting the presence of a selected analyte above a predetermined concentration in the fluid sample. The absorbent body and/or the assay include a color indicator that is able to provide a visual indication of the presence of one or more glycemic analytes present in the test sample.
Vertical flow assay device for detecting glucose concentration in a fluid sample
A glycemic management related analyte detecting assay device (10) and method are provided for detecting and quantifying analyte concentrations in a fluid sample. The assay device includes an absorbent body containing an assay forming a detection zone for receiving a fluid test sample. The absorbent body is provided in a chamber of the device. The assay can detect one or more of a glycemic analyte selected from the group consisting of fasting plasma blood glucose, oral glucose, % glycated hemoglobin, and fasting insulin concentrations. In one embodiment, a container includes an absorbent body having a plurality of superimposed membranes (30, 32, 34, 36) where each membrane contains a reactant and a color indicator for detecting the presence of a selected analyte above a predetermined concentration in the fluid sample. The absorbent body and/or the assay include a color indicator that is able to provide a visual indication of the presence of one or more glycemic analytes present in the test sample.
Component measurement device and component measurement device set
A component measurement device for measuring a component of interest in blood on a basis of optical characteristics of a mixture containing a color component produced by a color reaction between the component of interest in the blood and a reagent includes: a first light source configured to emit first irradiation light of a first predetermined wavelength to the mixture; and a second light source configured to emit second irradiation light of a second predetermined wavelength to the mixture, the second irradiation light to be used for estimation of a noise amount contained in a measured value of absorbance of the mixture measured by using the first irradiation light of the first light source, the noise amount being derived other than from the color component.